A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Launched by CSTONE PHARMACEUTICALS · Mar 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new experimental drug called CS5001 to see how safe it is and whether it can help patients with advanced solid tumors and lymphomas. This is the first time this drug is being tested in humans, and it aims to find out if it works well for people who have already tried other treatments without success. The study is currently looking for participants aged 65 to 74 who have specific types of cancer and are in need of new treatment options.

To be eligible for the trial, patients should have advanced solid tumors that cannot be surgically removed or certain types of lymphoma that have not responded to at least two previous treatments. Participants will need to have a life expectancy of more than three months and should be able to provide a sample of their tumor and blood for testing. Throughout the trial, participants will receive regular check-ups and monitoring to assess their health and how they respond to the treatment. It's important to note that there are some health conditions that could prevent someone from joining, so potential participants should discuss their individual situation with their doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • For solid tumor patients of dose escalation, they must have pathologically confirmed, unresectable advanced solid tumor with disease progression on or after at least 1 line of prior systemic therapy.
• • For Lymphoma patients of dose escalation, they must have pathologically confirmed Hodgkin and non-Hodgkin B-cell lymphoma as defined per 2016 World Health Organization(WHO) classification, with disease progression on or after at least 2 lines of prior systemic therapy.
• • For dose expansion, pathologically confirmed Mantle Cell Lymphoma(MCL, following at least two prior lines of systemic therapy including Bruton Tyrosine Kinase inhibitors), Diffuse Large B Cell Lymphoma(DLBCL, following at least two prior lines of systemic therapies), and Triple Negative Breast Cancer(TNBC, following at least 2 lines of systemic therapy for advanced disease) will be enrolled.
• • For dose escalation, with at least one evaluable lesion as defined per Response Evaluation Criteria in Solid Tumours(RECIST) v1.1 solid tumor or per 2014 Lugano Classification Criteria for lymphoma, respectively. For dose expansion, with at least one measurable lesion as defined per RECIST v1.1 solid tumor or per 2014 Lugano Classification Criteria for lymphoma, respectively.
• • Life expectancy \> 3 months.
• • Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.
• • Have adequate organ function.
• Exclusion Criteria:
• • Has disease that is suitable for local treatment administered with curative intent. For lymphoma, candidacy for hematopoietic stem cell transplantation based on the Investigator's judgment.
• • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
• • For dose expansion: Participation in other studies involving therapies targeting ROR1 prior to study entry and/or during study participation.
• • Has known central nervous system (CNS) lymphoma or solid tumor CNS metastasis that is either symptomatic, untreated, or requires therapy.
• • Has other acute or chronic medical or psychiatric conditions.
• • Has a diagnosis of immunodeficiency, or has an active autoimmune disease or other conditions that require systemic steroid therapy.
• • Has peripheral edema, pericardial effusion, or ascites indicated for medical intervention or limiting activity of daily life. Or with a known history of peripheral vasculopathies.
• • Patients with any active infections requiring systemic therapy within 2 weeks prior to the administration of the first dose of the study drug.
• • Patients known to be human immunodeficiency virus (HIV)-positive or have acquired immune deficiency syndrome (AIDS).
• • Significant cardiovascular disease within 6 months prior to the first dose of the study drug.
• • Significant screening electrocardiogram (ECG) abnormalities.
• • Has received major surgery, chemotherapy, definitive radiotherapy, target therapy, immunotherapy, or other anti-cancer therapy within 21 days prior to the administration of the first dose of the study drug.
• • Administration of a live vaccine within 28 days prior to the administration of the first dose of the study drug.
• • Has active graft versus host disease.
• • With known active alcohol or drug abuse.
• • Women who are pregnant or breastfeeding.